Moderna Inc (MRNA)

[axelvento]

PE is 4 way under value. Next 5 years growth rate is 13. Stock should trade at a Pe of 13


stay connected:

Under the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialization.The payment willbe expensed by Merck in the third quarter of 2022 and included in its non-GAAP results. Merck and Moderna will share costs and any profits equally under this worldwide collaboration.



$MRNA MULTIBAGGER$$$$$$$$$$$